Russian Heart Failure Journal 2007year Effect of lipid-normalizing therapy and optimal glycemic control on pronouncement of inflammation and CHF course in patients with type 2 diabetes mellitus
Effect of lipid-normalizing therapy and optimal glycemic control on pronouncement of inflammation and CHF course in patients with type 2 diabetes mellitus
Arutyunov G.P., Mkrtumyan A.M., Dzidzariya M.I., Bylova N.A., Chernyavskaya T.K.
Urgency. High prevalence and mortality of patients with a combination of type 2 DM and CHF along with the interrelation between their mechanisms of progression warrant development of a unified tactics for managing these patients and searching for possible ways to prevent complications. Aim. Evaluating the effect of optimal glycemic control (HbA11C≤7 %) and lipid-normalizing therapy on the course of CHF, progression of nephropathy and activity of inflammation in patients with II–IV FC (NYHA) CHF and type 2 DM. Materials and methods. Study enrolled 79 patients with CHF of ischemic genesis in combination with type 2 DM having a tight (HbA1C≤7%, n=39) or suboptimal glycemic control (HbA1C>7%, n=40). Dynamics of 6-min walking test, quality of life (QL), microalbuminuria (MAU), C-reactive protein (CRP), glycosylated hemoglobin, hospitalization rate and fatal outcomes were analyzed for 24 months. Results. Addition of simvastatin 40 mg daily to the therapy for CHF in combination with type 2 DM with optimal glycemic control results in significant reductions of CRP level by 36.8% and MAU by 19.5%.